Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method
Phase 1
Completed
- Conditions
- PainCancerColonic Disease
- Interventions
- Other: PlaceboDrug: GIC-1001 375 mg TIDDrug: GIC-1001 500 mg TIDDrug: GIC-1002 460 mg (equimolar to GIC-1001 500 mg)Drug: GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- gicare Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT02276768
- Locations
- 🇨🇦
Algorithme Pharma Inc., Montreal, Quebec, Canada
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- gicare Pharma Inc.
- Target Recruit Count
- 308
- Registration Number
- NCT01926444
- Locations
- 🇺🇸
Avail Clinical Research LLC, DeLand, Florida, United States
🇺🇸Mid-Atlantic Medical Research Centers, Hollywood, Maryland, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Colonic Diseases
- Interventions
- Drug: GIC-1001; 125 mg oral tabletsDrug: GIC-1001 matching placebo
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- gicare Pharma Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01738425
- Locations
- 🇨🇦
Algorithme Pharma Inc., Montreal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath